Relay Therapeutics RLAY
NASDAQ RLAY
$18.96 +0.47 (+2.54%)
At close: Oct 2, 2026 · 4:00 PM EDT

Relay Therapeutics (RLAY) Return on Sales [ROS] (2021 - 2026)

Updated

Relay Therapeutics (RLAY) posted Return on Sales [ROS] of -25949.71% for Q2 2026, down 14598.61 percentage points from -11351.11% a year earlier and down 23330.05 percentage points from the prior quarter.

Analysis

Relay Therapeutics (RLAY) Return on Sales [ROS] (2021 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Return on Sales [ROS] at Relay Therapeutics was -2999.37%, up 1106.23 percentage points year-over-year; for FY2025, it was -1971.59%, up 1750.48 percentage points from FY2024.

  • Annual Return on Sales [ROS] shows a five-year change of -1904.09 percentage points (FY2020 to FY2025).
  • In prior years, Relay Therapeutics' Return on Sales [ROS] was -3722.07% in FY2024 (-2261.96 pp), -1460.11% in FY2023 (+20210.78 pp), -21670.89% in FY2022 (-9630.68 pp) and -12040.21% in FY2021 (-11972.71 pp).
  • The Q2 2026 figure stands as the lowest quarterly Return on Sales [ROS] since Q2 2023.
  • On a year-over-year basis, Return on Sales [ROS] increased in 1 of the last eight quarters, with an average year-over-year change of -3710.15 percentage points.
  • The strongest year-over-year quarter for Return on Sales [ROS] in the past five years was Q2 2024, with a gain of 88103.98 percentage points; the weakest was Q2 2023, with a drop of 67799.56 percentage points.
  • According to Business Quant data, Return on Sales [ROS] for the three prior quarters was -2619.67% (Q1 2026), -866.14% (Q4 2025) and -3914.38% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 28.21%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 37.86%
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -3.52%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 32.97%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 20.57%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 34.95%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -133.21%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 28.37%
10 Relay Therapeutics 4.14 Bn 4.14 Bn - -25,949.71%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -25,949.71%
Mar 31, 2026 -2,619.67%
Dec 31, 2025 -866.14%
Sep 30, 2025 -3,914.38%
Jun 30, 2025 -11,351.11%
Mar 31, 2025 -1,105.21%
Dec 31, 2024 -3,722.07%
Sep 30, 2024 -3,794.57%
Jun 30, 2024 -1,013.67%
Mar 31, 2024 -903.00%
Dec 31, 2023 -1,460.11%
Sep 30, 2023 -291.95%
Jun 30, 2023 -89,117.65%
Mar 31, 2023 -44,768.58%
Dec 31, 2022 -28,794.86%
Sep 30, 2022 -24,968.60%
Jun 30, 2022 -21,318.08%
Mar 31, 2022 -14,969.21%
Dec 31, 2021 -11,944.09%
Sep 30, 2021 -9,157.66%
API Access

Relay Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=RLAY&period=max&api_key=YOUR_API_KEY